Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study (With Safety run-in) of Evorpacept (ALX148) in Combination With Cetuximab and Pembrolizumab in Patients With Refractory Microsatellite Stable Metastatic Colorectal Cancer

NCT05167409 is registered in ClinicalTrials.gov with University of Colorado, Denver as lead sponsor.

NCT NCT05167409
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05167409 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study (With Safety run-in) of Evorpacept (ALX148) in Combination With Cetuximab and Pembrolizumab in Patients With Refractory Microsatellite Stable Metastatic Colorectal Cancer
Lead sponsor
University of Colorado, Denver
Phase
Phase 2
Overall status
Terminated
Start date
July 28, 2022
Completion date
October 30, 2024
Enrollment
19 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

microsatellite stable metastatic colorectal cancer